Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease.
Crooke's changes
Cushing disease
corticotroph tumor
pituitary tumor regrowth and recurrence
pituitary tumors
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
10
2020
accepted:
01
03
2021
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Glucocorticoid excess in Cushing disease (CD) leads to negative feedback suppression, resulting in Crooke's hyaline change (CC) of nontumorous pituitary corticotrophs. We aimed to determine the predictive value of CC of nontumorous corticotrophs in CD. The retrospective chart review study included patients with clinical, biochemical, radiologic and outcome data and evaluable histopathology specimens from pituitary surgery for CD. The main outcome was remission of CD, defined by clinical features, biochemical testing, and corticosteroid dependency. Of 144 CD patients, 60 (50 women, mean age 43.6±14) had clinical follow-up, biochemical data and histopathology specimens that included evaluable nontumorous adenohypophysis. Specimens from 50 patients (83.3%) demonstrated CC in nontumorous corticotrophs, and 10 (16.7%) had no CC (including 3 with corticotroph hyperplasia). One patient with CC was lost to follow-up and one without CC had equivocal outcome results. During a mean (SD) follow-up period of 74.9 months (61.0), recurrent or persistent disease was documented in 18 patients (31.0%), while 40 (69.0%) were in remission. In patients with CC, the remission rate was 73.5% (95% CI, 59.7%-83.7%) (36/49), whereas it was 44.4% (95% CI, 18.9%-73.3%) (4/9) in patients with no CC. The combination of serum cortisol >138 nmol/L within a week of surgery coupled with absence of nontumorous CC greatly improved the prediction of recurrent or persistent disease. CC of nontumorous corticotrophs was observed in 83% of patients with CD, and most patients with CC experienced remission. Absence of CC in nontumorous corticotrophs may serve as a predictor of reduced remission in patients with CD.
Sections du résumé
Background
Glucocorticoid excess in Cushing disease (CD) leads to negative feedback suppression, resulting in Crooke's hyaline change (CC) of nontumorous pituitary corticotrophs. We aimed to determine the predictive value of CC of nontumorous corticotrophs in CD.
Methods
The retrospective chart review study included patients with clinical, biochemical, radiologic and outcome data and evaluable histopathology specimens from pituitary surgery for CD. The main outcome was remission of CD, defined by clinical features, biochemical testing, and corticosteroid dependency.
Results
Of 144 CD patients, 60 (50 women, mean age 43.6±14) had clinical follow-up, biochemical data and histopathology specimens that included evaluable nontumorous adenohypophysis. Specimens from 50 patients (83.3%) demonstrated CC in nontumorous corticotrophs, and 10 (16.7%) had no CC (including 3 with corticotroph hyperplasia). One patient with CC was lost to follow-up and one without CC had equivocal outcome results. During a mean (SD) follow-up period of 74.9 months (61.0), recurrent or persistent disease was documented in 18 patients (31.0%), while 40 (69.0%) were in remission. In patients with CC, the remission rate was 73.5% (95% CI, 59.7%-83.7%) (36/49), whereas it was 44.4% (95% CI, 18.9%-73.3%) (4/9) in patients with no CC. The combination of serum cortisol >138 nmol/L within a week of surgery coupled with absence of nontumorous CC greatly improved the prediction of recurrent or persistent disease.
Conclusions
CC of nontumorous corticotrophs was observed in 83% of patients with CD, and most patients with CC experienced remission. Absence of CC in nontumorous corticotrophs may serve as a predictor of reduced remission in patients with CD.
Identifiants
pubmed: 33815279
doi: 10.3389/fendo.2021.620005
pmc: PMC8013723
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
620005Informations de copyright
Copyright © 2021 Akirov, Larouche, Shimon, Asa, Mete, Sawka, Gentili and Ezzat.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Endocrinol. 2013 Mar 20;168(4):639-48
pubmed: 23371975
Eur J Endocrinol. 2007 Feb;156(2):203-16
pubmed: 17287410
J Clin Endocrinol Metab. 2001 Jan;86(1):117-23
pubmed: 11231987
J Clin Endocrinol Metab. 2007 Sep;92(9):3383-8
pubmed: 17595252
Endocr Pathol. 2020 Dec;31(4):330-336
pubmed: 32813227
J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31
pubmed: 26222757
J Neurooncol. 2019 Mar;142(1):171-181
pubmed: 30607704
Clin Endocrinol (Oxf). 2014 Mar;80(3):411-8
pubmed: 23895112
J Clin Endocrinol Metab. 2004 Mar;89(3):1131-9
pubmed: 15001598
J R Soc Med. 1986 May;79(5):262-9
pubmed: 3014145
Exp Clin Endocrinol Diabetes. 1999;107(3):183-9
pubmed: 10376443
J Neurosurg. 2001 Jul;95(1):1-8
pubmed: 11453376
Surg Neurol. 2000 Jan;53(1):77-81
pubmed: 10697237
J Clin Endocrinol Metab. 2011 Mar;96(3):632-42
pubmed: 21193542
Clin Endocrinol (Oxf). 2002 Jan;56(1):25-31
pubmed: 11849243
Brain Pathol. 2012 Jul;22(4):443-53
pubmed: 22697380
J Clin Endocrinol Metab. 2009 Jun;94(6):1897-903
pubmed: 19276234
Pituitary. 2015 Apr;18(2):217-24
pubmed: 25501318
Hum Pathol. 2021 Jan;107:87-95
pubmed: 33098891
Pituitary. 2018 Oct;21(5):490-498
pubmed: 30039432
Endocr Pathol. 2018 Jun;29(2):130-136
pubmed: 29453601
Arch Pathol Lab Med. 2011 May;135(5):640-6
pubmed: 21526962
J Clin Endocrinol Metab. 2008 Feb;93(2):358-62
pubmed: 18056770
J Clin Endocrinol Metab. 2007 Mar;92(3):976-81
pubmed: 17200171
J Clin Endocrinol Metab. 2010 Feb;95(2):601-10
pubmed: 20080848
Clin Endocrinol (Oxf). 2005 Nov;63(5):549-59
pubmed: 16268808
J Clin Endocrinol Metab. 2015 Aug;100(8):3165-71
pubmed: 26147609